Other Events ·
Clearmind Medicine enrolls first patients in trial of CMND-100 for Alcohol Use Disorder
CMNDClearmind Medicine Inc.
Clearmind Medicine Inc. announced the enrollment of its first patients with Alcohol Use Disorder (AUD) in the ongoing clinical trial evaluating CMND-100, a proprietary psychedelic-based treatment candidate. The initial two patients were enrolled at Hadassah Medical Center in Jerusalem, Israel, marking the first administration of CMND-100 to AUD subjects. This milestone follows previous evaluations of CMND-100 at multiple doses in healthy participants and represents significant progress toward key clinical milestones for safety, tolerability, pharmacokinetics, and preliminary efficacy. Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing non-hallucinogenic neuroplastogen-derived therapeutics for neuropsychiatric, metabolic, and addiction disorders.